Table 3.
Independent variables associated with 28-day mortality in SFTS patients according to univariate and multivariate Cox regression analyses.
| Independent Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P-Value | HR (95% CI) | P-Value | |
| IVIG dosage | 0.98 (0.97–1.00) | 0.007 | 0.98 (0.96–1.00) | 0.012 |
| IVIG duration | 0.54 (0.41–0.72) | <0.001 | ||
| NLR | 1.07 (0.99–1.16) | 0.111 | ||
| RDW | 1.14 (0.96–1.35) | 0.136 | ||
| PT | 1.44 (0.97–2.13) | 0.069 | 1.27 (0.72–2.24) | 0.415 |
| APTT | 1.02 (1.00–1.04) | 0.014 | 0.99 (0.96–1.03) | 0.591 |
| TT | 1.02 (1.01–1.03) | 0.002 | 1.01 (0.99–1.02) | 0.315 |
| D-dimer | 1.04 (1.01–1.07) | 0.012 | 1.00 (0.96–1.04) | 0.972 |
| Dizziness and headache | 0.42 (0.17–1.05) | 0.063 | 0.26 (0.09–0.78) | 0.016 |
| Corticosteroid therapy | 1.91 (0.85–4.29) | 0.118 | ||
| RhG-CSF therapy | 2.15 (0.74–6.24) | 0.160 | ||
| Plasma exchange | 2.38 (0.81–6.94) | 0.115 | ||
| Blood transfusion | 11.31 (1.53–83.62) | 0.017 | 7.16 (0.90–57.35) | 0.064 |
| Oxygen inhalation | 3.77 (1.13–12.58) | 0.031 | 2.27 (0.54–9.58) | 0.264 |
| Respiratory support | 2.85 (1.27–6.44) | 0.011 | 2.26 (0.80–6.44) | 0.126 |
IVIG dosage represents the cumulative dosage of IVIG; IVIG duration is defined as the number of days of IVIG treatment; IVIG, intravenous immunoglobulin; NLR, neutrophil-to-lymphocyte ratio; RDW, red cell volume distribution width; PT, prothrombin time; APTT, activated partial thromboplastin time; TT, thrombin time; RhG-CSF, recombinant human granulocyte colony-stimulating factor; HR, hazard ratio; CI, confidence interval.